Please select the option that best describes you:
How does the presence of PSMA negative lesions in a patient with mCRPC affect your decision to treat with Lutetium (177Lu) vipivotide tetraxetan?
If the majority of lesions are PSMA positive lesions, do you proceed with Lutetium, and if so, how do you treat or consider therapy to the PSMA negative lesion?
VISION excluded patients with more than or equal to 1 PSMA negative lesion meeting size criteria. If limited alternate options, would this still stop you from using lutetium?
Answer from: Radiation Oncologist at Community Practice
The tl;dr answer: If the patient met VISION criteria for exclusion based on PSMA-negative disease burden, then yes, I would most likely not recommend Pluvicto and would prefer alternative systemic options. Consider cabazitaxel if the patient has already seen docetaxel. Also, ensure the patient ...
Sign in or Register to read more